Flutamide

Generic Name: Flutamide

Brand Names: Eulexin

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₁F_₃N_₂O_₃

CAS Number: 13311-84-7

Unique Ingredient Identifier: 76W6J0943E

Background: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Indication: For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate

Associated Conditions: Stage B2-C metastatic Carcinoma of the Prostate, Stage D2 metastatic Carcinoma of the Prostate

Clinical Trials

Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Phase 2

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: goserelin acetate
Drug: flutamide
Drug: leuprolide acetate
Drug: triptorelin
Procedure: Definitive Treatment

First Posted Date: 2016-04-19

Last Posted Date: 2020-07-07

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT02742675

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Phase 2

Completed

Conditions: Castration-resistant Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Flutamide

First Posted Date: 2015-01-27

Last Posted Date: 2021-09-16

Lead Sponsor: Taro Iguchi, MD, PHD

Target Recruit Count: 104

Registration Number: NCT02346578

Locations: 🇯🇵
Osaka City University Graduate School of Medicine, Osaka, Japan

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

Phase 2

Completed

Conditions: Polycystic Ovary Syndrome (PCOS)

Interventions: Other: Placebo
Drug: Flutamide

First Posted Date: 2013-06-28

Last Posted Date: 2025-01-10

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 23

Registration Number: NCT01889199

Locations: 🇺🇸
UCaliforniaLA, Los Angeles, California, United States

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Drug: Bicalutamide
Drug: Abiraterone Acetate
Drug: Degarelix
Drug: Flutamide
Drug: Goserelin Acetate
Drug: Leuprolide Acetate
Drug: Nilutamide
Drug: Prednisone

First Posted Date: 2013-02-07

Last Posted Date: 2025-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 310

Registration Number: NCT01786265

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

Not Applicable

Terminated

Conditions: Hyperandrogenism
Polycystic Ovary Syndrome

Interventions: Drug: Flutamide
Drug: Progesterone
Drug: estrace

First Posted Date: 2011-09-02

Last Posted Date: 2018-06-04

Lead Sponsor: University of Virginia

Target Recruit Count: 4

Registration Number: NCT01428193

Locations: 🇺🇸
Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States

Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

Phase 3

Completed

Conditions: Prostatic Neoplasms, Locally Advanced

Interventions: Drug: Leuprorelin SR
Radiation: Radiotherapy
Drug: Flutamide

First Posted Date: 2010-05-13

Last Posted Date: 2015-07-29

Lead Sponsor: Takeda

Target Recruit Count: 273

Registration Number: NCT01122121

Locations: 🇫🇷
Clinique Mutualiste, Saint-etienne, France

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

Phase 3

Completed

Conditions: Adenocarcinoma, Prostate

Interventions: Drug: Cyproterone acetate
Drug: Medroxyprogesterone acetate
Drug: Venlafaxine
Drug: Leuprorelin
Drug: Flutamide
Drug: Placebo

First Posted Date: 2009-11-11

Last Posted Date: 2015-07-30

Lead Sponsor: Takeda

Target Recruit Count: 311

Registration Number: NCT01011751

Locations: 🇫🇷
Professor Jacques IRANI, Poitiers, France

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Radiation: Dose-Escalated Radiation Therapy
Drug: bicalutamide
Drug: flutamide
Drug: LHRH agonist (antagonist) therapy

First Posted Date: 2009-07-10

Last Posted Date: 2024-10-10

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 1538

Registration Number: NCT00936390

Locations: 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States

and more 514 locations

Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome

Phase 1

Active, not recruiting

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Placebo
Drug: Flutamide

First Posted Date: 2009-06-30

Last Posted Date: 2023-11-02

Lead Sponsor: University of Virginia

Target Recruit Count: 72

Registration Number: NCT00930228

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Leuprorelin
Drug: Flutamide

First Posted Date: 2009-01-06

Last Posted Date: 2015-07-29

Lead Sponsor: Takeda

Target Recruit Count: 341

Registration Number: NCT00817739

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy